Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QGLY - Funny Name Great Product. -- Ignore unavailable to you. Want to Upgrade?

To: Ken Fallon who wrote (8922)	9/13/1999 4:24:00 PM
From: drakes353	Read Replies (1) \| Respond to of 8960

Hey...I remember a time when something like this could get the stock to jump 1-2 points, easy. Check out the wording...."communications has been established". Funny, funny stuff. COLD-EEZE (R) to Expand Distribution Worldwide PR Newswire - September 13, 1999 07:45 The Quigley Corporation Establishes Communications With the Pharmaceutical Representatives of 49 Nations DOYLESTOWN, Pa., Sept. 13 /PRNewswire/ -- The Quigley Corporation (Nasdaq: QGLY) announced today that communications have been established with the pharmaceutical representatives of 49 countries worldwide regarding the distribution of the Company's COLD-EEZE (R) lozenges within their nations. In addition to the current drug filing in the United Kingdom and the appropriate filings being made in the Arab Middle East, communications are ongoing with Poland, Brazil, Singapore, South Africa, Japan, Taiwan, Malaysia and Azerbaijan. The Quigley Corporation's international marketing efforts expand upon marketing agreements previously established with several leading nations. In fact, COLD-EEZE shipments have already been delivered to the Bahamas as an initial Caribbean entry; a long-term multi-million dollar contract has been established with sales representatives in the People's Republic of China; and the first shipments of COLD-EEZE, under the name ALKOR (Hebrew for "no cold"), will be delivered to Israel this fall. "COLD-EEZE is one of the leading selling cough/sore throat drops in the United States and is among the top 10 branded products in the cold/allergy/sinus tablet category," says Guy Quigley, CEO of the Company. "The next corporate target is to ensure widespread proliferation throughout the world." Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition. The Quigley Corporation, a natural health and homeopathic drug company, is the maker of COLD-EEZE (R), and COLD-EEZE (R) homeopathic bubble gum, Sugar- free COLD-EEZE (R) and the BodyMate (TM) Nutrition and Weight Management Program. COLD-EEZE(R) is the only zinc gluconate glycine (ZIGG) (TM) lozenge proven in two double-blind studies to reduce the duration and severity of common cold symptoms. For more information, please contact Will Chelak, 609-683-9055 Ext. 151, or Tom Healey, 609-683-9055 Ext. 108, both of Integrated Marketing Services for The Quigley Corporation. SOURCE The Quigley Corporation